Expertise in
14
conditions

Marco Herling

Leipzig, SN, DE 
Expertise in
14
conditions
Leipzig, SN, DE 

Overview

Marco Herling practices practicing medicine in Leipzig, Germany.

Mr. Herling is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Chronic T-Cell Leukemia (CTCL), Prolymphocytic Leukemia, Adult T-Cell Leukemia, Bone Marrow Transplant, and Bone Graft.

He is actively involved in clinical research, co-authoring 164 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Leipzig, SN, Germany
Other Locations
Jena, TH, Germany
Koeln, NW, Germany
Bonn, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)
Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)
Enrollment Status: Terminated
Publish Date: December 02, 2019
Intervention Type: Drug
Study Phase: Phase 2

164 Total Publications

Prognostic relevance of RUNX1 mutations at acute myeloid leukemia diagnosis and as measurable residual disease marker before and after allogeneic stem cell transplantation.
Prognostic relevance of RUNX1 mutations at acute myeloid leukemia diagnosis and as measurable residual disease marker before and after allogeneic stem cell transplantation.
Journal: Haematologica
Published: May 14, 2026

Frequently Asked Questions about Marco Herling

Is Marco Herling a top-rated expert for Chronic T-Cell Leukemia (CTCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Marco Herling is classified as an Elite expert for Chronic T-Cell Leukemia (CTCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marco Herling participate in research or clinical trials?

Yes. Marco Herling has published 164 articles and abstracts on conditions like Chronic T-Cell Leukemia (CTCL). You can view a list of Marco Herling's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Herling's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile